NovoCure Ltd
NVCR
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.7B
Close$
$-7.68
153.3% downside
Current Fair Value
153.3% downsideOvervalued by 153.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.70 Billion |
|---|---|
| Enterprise Value | $1.84 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.22 |
| Beta | 0.99 |
| Outstanding Shares | 116,012,397 |
Return
| Return on Equity | -43.94% |
|---|---|
| Return on Assets | -18.68% |
| Return on Invested Capital | -26.97% |
Valuation & Multiples
| P/E Ratio | -11.22 |
|---|---|
| PEG | 18.39 |
| Price to Sales | 2.4 |
| Price to Book Ratio | 7.21 |
| Enterprise Value to Revenue | 2.63 |
| Enterprise Value to EBIT | -11.86 |
| Enterprise Value to Net Income | -13 |
| Total Debt to Enterprise | 0.13 |
| Debt to Equity | 0.69 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 23, 2026
EPS Estimate
$-0.33
Average shareholder expectationRevenue Estimate
$172.44 M
Average shareholder expectationNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
$-0.23
Average shareholder expectationRevenue Estimate
$182.28 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 18.75% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.02%▼ 90.10% |
|---|---|
| Total Invested | $399,039▼ 99.97% |
| Investors Holding | 6▼ 225.00% |
ESG Score
No data
About NovoCure Ltd
CEO: Asaf Danziger